Try our Advanced Search for more refined results
Health
-
February 19, 2026
Judge Denies Mylan And Aurobindo's Bid To Escape Trial
A Connecticut federal judge has once again rejected generic-drug makers' bid to escape a multistate lawsuit accusing them of engaging in an overarching antitrust conspiracy, saying the evidence supports the need for a jury trial on whether the companies colluded to fix prices and divvy up markets for dozens of generic drugs.
-
February 19, 2026
Texas Suit Says Sanofi Paid Kickbacks For Prescriptions
Texas Attorney General Ken Paxton sued Sanofi-Aventis US LLC in state court Thursday, accusing the pharmaceutical company of paying kickbacks to providers so they would prescribe Sanofi's drugs.
-
February 19, 2026
Prisoners Slam 'Unacceptable' Delay In Ga. Trans Care Suit
A group of transgender Georgia prisoners has accused state officials of dragging their heels in implementing a court order requiring the correctional system to resume hormone therapy treatments, asking a federal judge to force the state to begin notifying class members imminently.
-
February 19, 2026
Xerox Whistleblower Deal Cut May Hinge On Public Disclosures
A Texas appellate court wanted to know Thursday whether a trio of whistleblowers is entitled to a $48 million cut of a Medicaid fraud settlement with Xerox, asking whether prior public disclosures of the wrongdoing helped or hurt their case.
-
February 19, 2026
Outcome Execs Argue High Court Ruling Ends Restitution Bid
Former Outcome Health executives who were convicted of a nearly $1 billion fraud are again asking their trial judge to end restitution proceedings in their case, arguing recent U.S. Supreme Court precedent makes clear the judge lacks the necessary jury findings to decide the long-outstanding issue.
-
February 19, 2026
Red State AGs Back La. Bid To Halt Eased Abortion Pill Rules
A coalition of 21 Republican state attorneys general, led by Nebraska, urged a federal judge to grant Louisiana's bid to block the U.S. Food and Drug Administration's 2023 rules easing access to the abortion drug mifepristone, arguing that the policy undermines states' authority to enforce their own abortion laws and imposes a "pocketbook injury" on states.
-
February 19, 2026
Conn. Medical Office Faces 3 'Insomnia' Data Breach Suits
A Connecticut medical practice failed to secure its patients' and employees' private information ahead of a ransomware attack that likely affected thousands of people, then flouted its duty to provide the victims with proper notice, according to three proposed class actions filed in the past week.
-
February 19, 2026
Texas Panel Unsure Midwife Can Escape Abortion Order
A Texas appellate court pushed back on a midwife's assertion that a court order blocking her from providing abortions flouted the state's rules of civil procedure, saying Thursday she wasn't facing the lawsuit "for doing appendectomies."
-
February 19, 2026
Pharma Group Asks 1st Circ. To Ax RI's 340B Drug Price Law
A pharmaceutical trade group has urged the First Circuit to overturn a district court's order siding with a Rhode Island law that bars drug manufacturers from blocking hospitals and clinics from contracting with outside pharmacies to dispense discounted drugs under the federal 340B Discount Drug Program.
-
February 19, 2026
Hims & Hers Buying Eucalyptus For Up To $1.15B
Wellness platform Hims & Hers Health Inc. said Thursday it has agreed to acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion.
-
February 19, 2026
Northwell Health Should Beat Pension Plan Suit, Judge Says
Northwell Health inched closer to escaping a proposed class action alleging the hospital system hid cuts to workers' pension plans when converting to a cash-balance plan in the late 1990s, after a New York federal magistrate judge held disclosures about plan changes complied with federal benefits law.
-
February 19, 2026
Harvard Docs Get Censored Articles Permanently Restored
The Trump administration agreed to maintain the court-ordered restoration of articles penned by Harvard Medical School researchers that contained references to the LGBTQ+ community after they had previously been scrubbed from a government-hosted website.
-
February 19, 2026
Trump Orders Weedkiller Glyphosate Production Hike
President Donald Trump issued an executive order late Wednesday aimed at ramping up the production of glyphosate, the active ingredient in the weedkiller Roundup that has been accused of causing cancer in scores of lawsuits, including one on appeal to the U.S. Supreme Court.
-
February 19, 2026
Healthcare Co., Nurse Agree To Collective In OT Suit
A healthcare company and a nurse claiming he wasn't paid overtime agreed that a collective should be certified, telling an Ohio federal court Thursday that doing so will allow efficiency in the case and increase the possibility of a deal.
-
February 18, 2026
Trans Health Org Sues To End 'Unconstitutional' FTC Inquiry
The World Professional Association for Transgender Health on Wednesday sued over the Federal Trade Commission's recent consumer protection investigation into the major transgender medical group, claiming the probe is an unconstitutional attack aimed at undermining access to gender-affirming care.
-
February 18, 2026
Blue Shield Of Calif. Says 'Ghost Network' Action Falls Flat
Trouble finding a mental health care therapist is unfortunate but not something that an entire class action can be based on, argued Blue Shield of California, urging a federal judge to dismiss a suit accusing the company of maintaining a "ghost network" directory of providers who don't exist or don't accept new patients.
-
February 18, 2026
Government Drops Case Over Referrals-For-Kickback Scheme
A Texas federal judge tossed an indictment accusing about a dozen physicians and pharmacists of running a sprawling patient referral scheme, ending allegations that the pharmacists gave the doctors kickbacks in exchange for expensive prescriptions fillable at specific pharmacies.
-
February 18, 2026
Sandoz's Case Against Amgen Over Enbrel Biosimilar Tossed
A Virginia federal court found that Sandoz Inc. should have brought its claims accusing Amgen of blocking competition for Enbrel in a previous patent dispute over the blockbuster autoimmune disease treatment.
-
February 18, 2026
RFK Jr.-Founded Group Seeks Role In Vaccine Lawsuit
An organization founded by Robert F. Kennedy Jr. asked a Massachusetts federal judge on Wednesday to let it join the U.S. Department of Health and Human Services secretary as a defendant in a lawsuit challenging recent changes to childhood vaccination schedules so the group can pursue counterclaims against the plaintiffs.
-
February 18, 2026
NY Judge Trims Umbilical Cord Blood Co. Investor Suit
A New York federal judge has trimmed a securities class action accusing Global Cord Blood Corp. and others of orchestrating and trying to cover up a scheme in which hundreds of millions of dollars were transferred from Global Cord's cash reserves to its former parent company's founder and other businesses.
-
February 18, 2026
J&J Unit Appeals $442M Catheter Antitrust Loss To 9th Circ.
Johnson & Johnson's Biosense Webster health tech unit urged the Ninth Circuit to overturn a California federal jury's $147 million antitrust verdict — later upped to $442 million — over the company withholding cardiac mapping support to hospitals using third-party reprocessed catheters, saying Innovative Health LLC didn't prove its allegations of unlawful tying.
-
February 18, 2026
Medtronic Exec Alleges Retaliatory Firing For Whistleblowing
Minnesota-based medical device company Medtronic Inc. fired an executive for raising concerns that the company artificially boosted its sales figures routinely, he told a Colorado state court.
-
February 18, 2026
Meta Pixel Tracking Suit Tossed Over Lack Of Standing
A North Carolina federal judge has ruled that a prospective class of Nurse.com users lacked standing to sue the website's operator for Video Privacy Protection Act violations for allegedly sharing customers' information with Meta Platforms Inc. without permission.
-
February 18, 2026
4th Circ. Backs Military Policy Banning HIV-Positive Enlistees
The Fourth Circuit on Wednesday upheld a U.S. Department of Defense policy that bans HIV-positive Americans from enlisting, deferring to the military's judgment that it must have healthy and fit service members who do not require consistent treatment for chronic medical conditions.
-
February 18, 2026
Texas AG Says Hospital Violated Gender-Affirming Care Ban
Texas Attorney General Ken Paxton sued the Children's Health System of Texas on Wednesday, alleging it performed gender-affirming care on children through puberty blockers and cross-sex hormones despite a state law banning the treatments.
Expert Analysis
-
A Potential Shift In FDA's Approach To Drug Trial Design
Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.
-
Opinion
SNAP Rule Confusion Risks A Compliance Crisis
Recent Supplemental Nutrition Assistance Program food restriction waivers pose a compliance crisis for legal practitioners advising food retailers, amid higher costs and lack of a coherent national standard, says Tyson-Lord Gray at Yeshiva University’s Benjamin N. Cardozo School of Law.
-
Series
Trivia Competition Makes Me A Better Lawyer
Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.
-
What FDA Guidance Means For The Future Of Health Software
Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.
-
Opinion
Federal Preemption In AI And Robotics Is Essential
Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.
-
Series
Law School's Missed Lessons: What Cross-Selling Truly Takes
Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.
-
How State FCA Activity May Affect Civil Fraud Enforcement
A growing trend of state attorneys general enforcing their False Claims Act analogues independently of the U.S. Department of Justice carries potential repercussions for civil fraud enforcement and qui tam litigation considerations, say Li Yu at Bernstein Litowitz, Ellen London at London & Naor and Gwen Stamper at Vogel Slade.
-
Wage-Based H-1B Rule Amplifies Lottery Risks For Law Firms
Under the wage-based H-1B lottery rule taking effect Feb. 27, law firms planning to hire noncitizen law graduates awaiting bar admission should consider their options, as the work performed by such candidates may sit at the intersection of multiple occupational classifications with differing chances of success, says Jun Li at Reid & Wise.
-
Series
Judges On AI: Practical Use Cases In Chambers
U.S. Magistrate Judge Allison Goddard in the Southern District of California discusses how she uses generative artificial intelligence tools in chambers to make work more efficient and effective — from editing jury instructions for clarity to summarizing key documents.
-
Assessing Compliance Risks Around TrumpRx Participation
As there are novel compliance obligations and potential political opposition related to the new TrumpRx online drug platform, companies intending to participate on the site should consider the pressure points that are likely to draw enforcement scrutiny, say attorneys at Sheppard.
-
California's New Privacy Laws Demand Preparation From Cos.
An increase in breach disclosures is coinciding with California's most comprehensive privacy and artificial intelligence legislation taking effect, illustrating the range of vulnerabilities organizations in the state face and highlighting that the key to successfully managing these requirements is investing in capabilities before they became urgent, says Camilo Artiga-Purcell at Kiteworks.
-
Series
Trail Running Makes Me A Better Lawyer
Navigating the muddy, root-filled path of trail marathons and ultramarathons provides fertile training ground for my high-stakes fractional general counsel work, teaching me to slow down my mind when the terrain shifts, sharpen my focus and trust my training, says Eric Proos at Next Era Legal.
-
Predicting Actual Impact From CDC's New Vaccine Guidance
Recent federal changes to the childhood immunization schedule, reducing the number of vaccine recommendations from 18 to 11, do not automatically create enforceable obligations for parents, schools or healthcare providers, but may spur litigation and other downstream effects on school policies and state guidelines, says Mehdi Sinaki at Michelman & Robinson.
-
AI Scientific Discovery Order Implications For Life Sciences
President Donald Trump's November executive order establishing a government effort to use artificial intelligence to accelerate scientific discovery has the potential to leverage significant federal resources and data to support research, drug and device approvals, and AI model training in the life sciences sector, say attorneys at Hogan Lovells.
-
What Rescheduling Means For Cannabis Labels, Marketing
The proposed reclassification of cannabis is expected to bring heightened scrutiny of labeling, advertising and marketing from the U.S. Food and Drug Administration and the Federal Trade Commission, but the brands that tighten evidence, standardize operations and professionalize marketing controls now will see fewer surprises and better outcomes, say attorneys at Wilson Elser.